Cure My Disease

Don't miss your cure!

 Log in / Sign up

Metabolic effects of switching from injectable semaglutide to tirzepatide: a retrospective study of the LMC diabetes registry

NCT ID NCT07889453

NEW Sponsor: LMC Diabetes & Endocrinology Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 22, 2026 · Last updated Oct 22, 2026

Summary

The goal of this retrospective observational study is to evaluate the effectiveness of switching from injectable semaglutide to tirzepatide in adults living with type 2 diabetes (T2D) and, descriptively, in a smaller cohort of adults living with obesity without diabetes, using clinical data from the LMC Diabetes Registry. The study has two co-primary objectives: 1) to assess change in body weight from baseline to follow-up (6-12 months) among adults living with T2D who switched from injectable semaglutide to tirzepatide, and 2) to assess change in body weight over the same period among adults living with obesity without diabetes who switched. Secondary objectives will compare changes in body mass index (BMI), estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio (uACR), waist circumference, blood pressure, alanine transaminase (ALT), lipids, and insulin use from baseline to follow-up between adults living with T2D who switched to tirzepatide and a propensity score-matched group of adults living with T2D who continued semaglutide.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 650 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study populations will include adults living with T2D and adults living with obesity without diabetes, who switched from injectable semaglutide to tirzepatide, or adults living with T2D who were prescribed injectable semaglutide and did not switch to tirzepatide.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for T2D Cohort: * Age 18 years old or older * A clinical diagnosis of T2D ≥ 1 year * Baseline HbA1c ≥ 7.5% * ≥ one HbA1c value up to 6 months (+ 90 days) prior to index date * ≥ one body weight value up to 6 months (+ 90 days) prior to index date * Initiated injectable semaglutide or switched from injectable semaglutide to tirzepatide between January 1, 2022, and December 31, 2025 * Use of injectable semaglutide for ≥ 3 months for both the control and switch cohort * If using real-time continuous glucose monitoring (rtCGM) or intermittently scanned continuous glucose monitoring (isCGM), CGM use for ≥ 3 months * Seen by an LMC endocrinologist in the last 18 months as of the query date * Informed data consent for their medical record data to be used for research purposes Inclusion Criteria for Obesity (non-diabetes) Cohort: * Age 18 years old or older * BMI ≥ 30 kg/m2 * Baseline HbA1c \< 6.5% * ≥ one HbA1c value up to 6 months (+ 90 days) prior to index date * ≥ one body weight value up to 6 months (+ 90 days) prior to index date * Initiated injectable semaglutide and switched from injectable semaglutide to tirzepatide between January 1, 2022, and December 31, 2025 * Use of injectable semaglutide for ≥ 3 months * Seen by an LMC endocrinologist in the last 18 months as of the query date * Informed data consent for their medical record data to be used for research purposes Exclusion Criteria: * Clinical diagnosis of type 1 diabetes or latent autoimmune diabetes in adults * Prior use of tirzepatide * Were pregnant at the time of semaglutide initiation or semaglutide-to-tirzepatide switch or became pregnant during follow-up period * Bariatric surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Type 2 diabetes (T2D)

Contacts and locations

Locations

  • LMC Diabetes & Endocrinology Ltd.

    Toronto, Ontario, M4G 3E8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.